All In Biotech

Free tool

FAERS Monitor: Zelsuvmi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217424 or its brand name (Zelsuvmi, Berdazimer Sodium). Reports on generic versions are filed under their own applications.

Reports

95

Serious

0

0% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • application site pain46
  • application site erythema31
  • application site pruritus12
  • application site vesicles9
  • application site discolouration8
  • application site irritation8
  • application site rash8
  • application site exfoliation6
  • wrong technique in product usage process6
  • application site inflammation5
  • application site eczema4
  • application site scab4
  • application site swelling4
  • application site burn3
  • application site dermatitis3

Reports by year received

View as table
YearReports
202519
202676

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,064 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site eczemaSignal410680.63996.631,199
application site inflammationSignal5803.0341.63,232
application site dermatitisSignal3713.4233.81,477
application site painSignal46463.3376.320,739
application site discolourationSignal8436.8224.93,051
application site scabSignal4410.8157.31,249
application site exfoliationSignal6323.0148.81,615
application site vesiclesSignal9307.7165.22,450
application site erythemaSignal31262.2196.37,807
application site swellingSignal4177.868.1537
application site irritationSignal8142.473.4987
application site burnSignal3134.944.3276
application site rashSignal8128.966.4891
application site pruritusSignal12117.269.01,269
wrong technique in product usage processSignal66.63.023

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.